Rituximab (anti-CD20)

Rituximab (anti-CD20)

• CAS Number: 174722-31-7
• UNSPSC Description: Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1].
• Target Antigen: CD20
• Type: Inhibitory Antibodies
• Related Pathways: Immunology/Inflammation
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/rituximab-anti-cd20.html
• Purity: 99.10
• Solubility: 10 mM in H2O
• Smiles: [Rituximab (anti-CD20)]
• Molecular Weight: 144544.44
• References & Citations: [1]Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.|[2]Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.|[3]Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.
• Shipping Conditions: Blue Ice
• Storage Conditions: Store at 4°C for 2 years, do not freeze
• Clinical Information: Launched